Indications.
John
J
Oldham
D000293:Adolescent; D000927:Anticonvulsants / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D017277:Drug Approval; D019317:Evidence-Based Medicine; D006801:Humans; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D014635:Valproic Acid / Q000627:therapeutic use*
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D014635:Valproic Acid; D018967:Risperidone